EXS74539: A New LSD1 Inhibitor for Hard-to-Treat Solid Tumors, Including Prostate Cancer

/in , , /by

EXS74539, also called REC-4539, is an experimental cancer drug designed to block LSD1, a protein that helps some cancer cells grow and survive even when standard treatments fail. It is being tested in a phase 1 trial on people with selected solid tumors, including small-cell lung cancer, prostate cancer, ovarian cancer and others. This early-stage […]

Read more

TSL2109: A Novel Dual-Target Cancer Drug for Resistant Prostate Cancer

/in , , /by

TSL2109 is an experimental oral cancer drug being studied in people with advanced solid tumors, especially metastatic castration-resistant prostate cancer (aka androgen pathway modulation resistant prostate cancer, or APMR, God save us!) and advanced hormone receptor–positive, HER2-negative breast cancer. It is designed to hit two important targets at once, CDK4/6 and DYRK2, which may help […]

Read more

HY809382: PRC2 Degrader Which Works With EZH2 Inhibitors Resistant Prostate Cancer

/in /by

Prostate cancer becomes especially hard to treat when it turns resistant to hormone therapies like enzalutamide, largely because of a protein complex called PRC2 that shuts down genes needed to fight tumors. PRC2’s key parts, EZH2 and EED, fuel cancer growth, immune evasion, and drug resistance in prostate tumors, as well as others like endometrial […]

Read more

QL535: CD2-Based PSMA T-Cell Engager Maintains Anti-Tumor Activity in Advanced Prostate Cancer Models

/in , /by

PSMA-targeted T-cell engagers have struggled in solid tumors because they don’t activate T cells strongly enough and the immune cells become exhausted quickly. QL535 solves this problem by adding a second co-stimulatory signal through CD2, a molecule on T cells that’s abundant in prostate cancer tumors. Researchers analyzed immune cells from 14 advanced prostate cancer […]

Read more

MMAE-Based LIV1 ADC Achieves Sustained Tumor Control in Prostate Cancer Models

/in , /by

LIV1, a zinc transporter protein, sits on the surface of 72% of prostate tumors with minimal expression in healthy tissues. This makes it an ideal target for antibody-drug conjugates, a therapeutic class combining antibody specificity with potent cytotoxic payloads. Researchers developed 48D6, a humanized anti-LIV1 monoclonal antibody with substantially improved pharmacokinetics compared to previous versions. […]

Read more

PRINCE Trial Final Results: Lu-PSMA-617 + Pembrolizumab Shows Deep Responses in Advanced mCRPC

/in , , /by

The PRINCE trial has delivered final results showing promise for treating metastatic castration-resistant prostate cancer (mCRPC) with the combination of 177Lu-PSMA-617 (Pluvicto) and pembrolizumab. Published in The Lancet Oncology on April 1, 2026 , this single-arm, phase 1b/2 trial enrolled 37 heavily pretreated men (median age 72, 73% prior docetaxel, 100% prior AR inhibitors) who […]

Read more

UPDATE: Phase 1 Trial for RAD 402 Dosed the First Patient

/in , , /by

Following our previous article, we are pleased to report that patient dosing has commenced in this trial. First patient has been dosed in this Phase 1 dose-escalation trial evaluating RAD 402, an anti-KLK3 (PSA) monoclonal antibody radiolabeled with Terbium-161 (Tb-161), in patients with advanced prostate cancer previously treated with standard therapies. Following our past article, […]

Read more

Phase 1 Trial: Dual-Target ADC IDE034 Targets B7-H3/PTK7 in Prostate Cancer

/in , , /by

A promising new bispecific antibody-drug conjugate (ADC) known as IDE034 is entering early clinical testing in patients with advanced solid tumors, including prostate cancer, marking a potential step forward in precision oncology. This Phase 1a/1b trial, which began dosing its first patient in February 2026, targets tumors expressing both B7-H3 and PTK7, two surface proteins […]

Read more